COMPARISON OF EFFICACY BETWEEN 12-WEEK SOFOSBUVIR/VELPATASVIR (SOF/VEL) REGIMEN COMBINED WITH PRE-USE TENOFOVIR ALAFENAMIDE (TAF) FOR HCV/HBV COINFECTION AND SOF/VEL ALONE FOR HCV MONOINFECTION

Conference Reports for NATAP

The Liver Meeting
AASLD 2025
Washington, D.C.
November 7-11, 2025


COMPARISON OF EFFICACY BETWEEN 12-WEEK SOFOSBUVIR/VELPATASVIR (SOF/VEL) REGIMEN COMBINED WITH PRE-USE TENOFOVIR ALAFENAMIDE (TAF) FOR HCV/HBV COINFECTION AND SOF/VEL ALONE FOR HCV MONOINFECTION

	AASLD 2026 Denver